BOSTON, January 11, 2021 / PRNewswire / – Valo Health LLC (Valo), the technology company dedicated to transforming the process of drug discovery and development and accelerating the creation of life-changing drugs, closed a $ 190 million Series B funding and unveiling of selected therapeutic programs. Valo will discuss these programs in more detail at JP Morgan’s 39th Annual Healthcare Conference on January 12, 2021, To 4:20 p.m. EST (link below).
Valo creates a new systems approach to drug discovery and development. By combining its unique human-centric dataset (over 125 million patient years) with its Opal computing platformMT Valo brings the power of patient data and machine learning calculations throughout the drug development lifecycle. The result of this systems approach has been the rapid development of several key preclinical programs that have made significant progress on treatment profiles notoriously difficult to target. Here are some initial examples from Valo’s oncology portfolio:
- NAMPT: An opportunity made possible by the development of a therapy that uniquely avoids the mechanistic toxicology associated with the target, allowing the treatment of the main hematological and solid malignancies through a synthetic approach to the lethal metabolism of cancer.
- PARP1: a key protein involved in DNA repair and programmed cell death that has been clinically validated; centrally penetrating inhibitor to unlock the potential treatment of brain metastases, glioblastoma and other brain tumors.
- USP28: a deubiquitinase where the selective and specific targeting activated by Opal can allow a targeted approach to cancers induced by c-myc.
- HDAC3: A potential first-class opportunity to enable a synthetic lethality approach for the treatment of particular solid tumors.
“We have made huge strides in creating a fully integrated platform to accelerate the drug discovery and development process, making it much more efficient and less expensive to deliver life-saving treatments to patients,” said declared the founder and CEO of Valo, David Berry. “In less than two years, we have been able to develop our Opal computing platform and make significant progress on a number of programs, to achieve our ultimate goal of helping patients with major illnesses in our three therapeutic areas, cancer , cardiovascular disease and neurodegenerative disease. We’re excited to share some of the progress we’ve made on our journey to new cancer therapies with the combined power of Opal, Big Data, and a world-class team of experts. “
Valo raised $ 190 million in privileged equity through a series B financing, bringing its total capital raised to more than $ 285 million. The funding was led by the Public Sector Pension Investment Board (PSP Investments). All of Valo’s existing major investors, including Flagship Pioneering, and several new institutional investors, including Invus Public Equities, HBM Healthcare Investments, Atinum Investment and Mirae Asset Capital, are joining the Series B financing. The Series B proceeds will support the continued discovery and development of therapeutic programs and will further strengthen the Company’s proprietary Opal IT platform, working capital and other corporate goals.
“We are entering a period of monumental growth and evolution in the biotech industry,” said Edouard van Gelderen, Senior Vice-President and Chief Investment Officer, PSP Investments. “PSP is keen to invest in innovative cutting edge technology that can improve people’s lives. We are proud to support the extraordinary work that Valo is doing to identify ways to accelerate the creation of treatments for some of the most complex diseases in the world.
Valo’s Opal computing platformMT is the first end-to-end drug development platform that fully integrates human-centric data and artificial intelligence / machine learning, to accelerate the drug discovery and development process. Using Opal, Valo scientists were able to identify previously unsuspected associations between genetic markers and disease, which identify specific changes in gene activity with an initial focus on oncology, neurodegenerative diseases and cardiovascular.
The direct audio (non-video) live link for that of David Berry virtual session at the JP Morgan Healthcare conference on January 12, 2021, at 4:20 can be accessed using the following: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35837-valo-health/webcast?gpu_only=true&kiosk=true
And following the conference of Valo LinkedIn page
Valo Health, LLC (Valo) is a technology company that uses human-centric data and machine-learning calculations to transform the process of drug discovery and development. By integrating data throughout the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reduce costs, time and failure rate. The company’s Opal IT platform™, a fully integrated, component-based, end-to-end drug development platform offers a unique approach to therapeutic development, which enables Valo to advance a strong portfolio of candidates in the areas of cardiovascular disease, oncology and cancer. neurodegeneration. Founded by Flagship pioneer and headquartered at Boston, Massachusetts, Valo has offices in Watertown, Massachusetts, San Francisco, California, Princeton, New Jersey, and in Branford, Connecticut. To learn more, visit www.valohealth.com.
SOURCE Valo Santé, LLC